KPV Reference
Educational, not medical advice reference for KPV: Recovery, Immune; regulatory status, evidence posture, source review, and schedule notes. Als…
Plain English
- What it is
- KPV is a very small peptide made of just three building blocks (a tripeptide). It is not approved by the FDA as a medicine, and it is sold as a research chemical, not a treatment.
- What people use it for
- In the peptide community, people talk about KPV as a way to calm inflammation, mostly around gut-irritation and skin-irritation themes. This use is experimental and is not a proven human therapy.
- What the science shows
- Almost all of the evidence comes from animal studies, mostly mice with lab-induced gut inflammation, where KPV lowered signs of inflammation. There is no human trial program for KPV by itself, so its effects in people remain unproven.
- The catch
- KPV is not an approved drug and the human evidence is thin, so claims about it should be treated as unverified. US regulators are still reviewing whether it can even be used in pharmacy compounding, with an FDA advisory committee set to weigh it in July 2026.
Reference summary
Preclinical literature documents anti-inflammatory effects in rodent colitis models and transport via PepT1 in intestinal epithelium. Direct human clinical evidence for standalone KPV protocols is limited.
Regulatory and posture
- Categories
- Recovery, Immune
- Aliases
- Lysine-Proline-Valine, α-MSH (11-13) tripeptide
- Evidence posture
- preclinical - Mostly rodent colitis and dermatitis data. Human clinical evidence for KPV itself is limited.
- Regulatory status
- No FDA-approved KPV drug label. KPV is the C-terminal tripeptide fragment of α-MSH and is studied as an anti-inflammatory compound, primarily in animal models of colitis and dermatitis. On April 16, 2026, FDA published a Federal Register notice (docket FDA-2025-N-6895) scheduling a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 to consider KPV (free base and acetate), along with BPC-157, TB-500, and MOTS-c, for inclusion on the 503A Bulks List. At that meeting the committee narrowly recommended inclusion, against FDA's own reviewers; the recommendation does not bind FDA and KPV is not permitted for 503A compounding unless and until FDA completes rulemaking.
- Content review status
- research reference
Selected public sources
- FDA bulk drug substances with significant safety risks
- FDA Federal Register notice (Apr 16, 2026): Pharmacy Compounding Advisory Committee meeting July 23-24, 2026 on bulk drug substances nominated for the 503A Bulks List (incl. BPC-157, TB-500, KPV, MOTS-c on July 23; Emideltide/DSIP, Semax, Epitalon on July 24)
- PubMed: Dalmasso 2008 PepT1-mediated KPV tripeptide intestinal-inflammation study (Gastroenterology)
Related tools
- Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
- BAC water calculator - Solve BAC water volume for a target concentration.
- Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
- Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.
For research and educational purposes only. Not medical advice.